A machine learning algorithm for stratification of risk of cardiovascular disease in metabolic dysfunction-associated steatotic liver disease
European Journal of Internal Medicine · 2024
DOI: 10.1016/j.ejim.2024.07.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Internal Medicine, 2024. Verfasst von Naoki Shibata und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Ogaki Municipal Hospital, Ogaki, Japan. Hauptthemen laut MEDLINE: Machine Learning, Cardiovascular Diseases. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 36 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Steatotic liver disease (SLD) is associated with adverse cardiac events. Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as a condition characterized by the abnormal accumulation of hepatic lipids that is closely linked to five metabolic disorders: overweight or obesity, impaired glucose regulation, hypertension, hypertriglyceridemia, and low high-density lipoprotein-cholesterol. This retrospective study aimed to stratify the risk of cardiac events in patients with MASLD. METHODS: Patients diagnosed with MASLD through ultrasonography were evaluated. We implemented a machine learning-based approach using a survival classification and regression tree (CART) model to stratify patients based on age, and the number of risk scores was investigated as a predictor of adverse outcomes in the derivation cohort. The primary outcomes were major adverse cardiac events (MACE) including cardiac death, nonfatal myocardial infarction, and revascularization due to coronary artery disease. RESULTS: Among 2,962 patients (median age, 62 years; men, 53.5 %), the distribution of risk factors was as follows: one (10.8 %), two (28.5 %), three (33.0 %), four (19.9 %), and five (7.8 %). Over a median follow-up period of 6.8 years, 170 (5.7 %) patients experienced MACE. In the derivation cohort of 2,073 patients, the CART model identified age ≥60 years old and risk factors ≥4 as significant predictors of MACE. These findings were corroborated in a validation cohort of 889 patients. Patients meeting both criteria exhibited the highest risk of MACE (log-rank test, p < 0.001). CONCLUSIONS: Patients aged ≥60 years old with risk factors ≥4 indicates at high risk of MACE in patients with MASLD. This risk stratification system provides a practical tool for identifying high-risk individuals in the MASLD population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Ogaki Municipal Hospital, Ogaki, Japan.
- Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki, Japan; Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
- Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki, Japan.
- Department of Cardiology, Ogaki Municipal Hospital, Ogaki, Japan. Electronic address: morishima-i@muc.biglobe.ne.jp.
Zitieren
APA
Shibata, N., Morita, Y., Ito, T., Kanzaki, Y., Watanabe, N., Yoshioka, N., Arao, Y., Yasuda, S., Koshiyama, Y., Toyoda, H., & Morishima, I. (2024). A machine learning algorithm for stratification of risk of cardiovascular disease in metabolic dysfunction-associated steatotic liver disease. European Journal of Internal Medicine. https://doi.org/10.1016/j.ejim.2024.07.005
Vancouver
Shibata N, Morita Y, Ito T, Kanzaki Y, Watanabe N, Yoshioka N, et al. A machine learning algorithm for stratification of risk of cardiovascular disease in metabolic dysfunction-associated steatotic liver disease. European Journal of Internal Medicine. 2024. doi:10.1016/j.ejim.2024.07.005
BibTeX
@article{Shibata2024,
author = {Shibata, Naoki and Morita, Yasuhiro and Ito, Takanori and Kanzaki, Yasunori and Watanabe, Naoki and Yoshioka, Naoki and Arao, Yoshihito and Yasuda, Satoshi and Koshiyama, Yuichi and Toyoda, Hidenori and Morishima, Itsuro},
title = {A machine learning algorithm for stratification of risk of cardiovascular disease in metabolic dysfunction-associated steatotic liver disease},
journal = {European Journal of Internal Medicine},
year = {2024},
doi = {10.1016/j.ejim.2024.07.005}
}
EUVIMED